Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Sultan Qaboos Univ Med J 8(1): 1119 Braun V, Clarke V (2021) Thematic analysis: a practical guide
A perceived reduction in the desire to smoke was reported by participants while using GLP-1
Conflict of interest: MH has provided consultancy services to AstraZeneca, Novo Nordisk, Merck & Co., and HoffmanLa Roche with respect to incretin-targeted therapeutics and has received investigator-initiated research grants from Novo Nordisk and Merck & Co
In stock Description Tags Additional information Reviews Description Additional information
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury
With the results of the FLOW trial anticipated next year, as well as high rates of obesity and CVD in type 1 diabetes, there remains an unmet need for additional mechanistic and CVD/kidney outcome studies of GLP1-RAs in the population with type 1 diabetes and CKD [50]
:max_bytes(150000):strip_icc():focal(749x311:751x313)/Gabriel-IglesiasMayim-Bialik-and-Valerie-Bertinelli-060926-5ce5ab701dc546efb795b828cec51c2c.jpg)
